Haemophilia A and B are rare congenital, recessive X-linked disorders caused by lack or
deficiency of clotting factor VIII (FVIII) or IX (FIX), respectively. The severity of the disease …

Antibodies and antibody-derived macromolecules have established themselves as the
mainstay in protein-based therapeutic molecules (biologics). Our knowledge of the structure …

The high selectivity and affinity of antibodies toward their antigens have made them a highly
valuable tool in disease therapy, diagnosis, and basic research. A plethora of chemical and …

Congenital haemophilia A (factor VIII deficiency) and B (factor IX deficiency) are X-linked
bleeding disorders. Replacement therapy has been the cornerstone of the management of …

Background Fitusiran, an investigational small interfering RNA therapy, reduces
antithrombin production to rebalance hemostasis in people with hemophilia A or B, with or …

Hemophilia A (HA) and hemophilia B (HB) are the most common severe bleeding disorders.
Replacement therapy, providing the missing coagulation factor, has been the mainstay of …

Prophylactic factor VIII (FVIII) has dramatically improved haemophilia A treatment,
preventing joint bleeding and halting the deterioration of joint status. FVIII products with an …

Emicizumab, a bispecific monoclonal antibody, bridges activated factor IX (FIXa) and FX,
replacing the function of missing FVIIIa to restore effective hemostasis in persons with …

Systemic diseases of liver origin (SDLO) are complex diseases in multiple organ systems,
such as cardiovascular, musculoskeletal, endocrine, renal, respiratory, and sensory organ …

Emicizumab bridges activated factor IX (FIX) and FX to restore the tenase function mediated
by activated FVIII (FVIIIa), which is deficient in people with haemophilia A (PwHA). Unlike …